Coya Therapeutics Inc. is a biopharmaceutical company focused on the development of regenerative medicines to treat neurodegenerative and autoimmune diseases. Central to its mission is the advancement of innovative treatments that leverage immunotherapy and stem cell technology. The company's research and development efforts target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to provide therapeutic solutions where current options are limited. Coya Therapeutics is particularly noted for its emphasis on utilizing regulatory T-cells to modulate the immune system and potentially slow disease progression. This focus places Coya Therapeutics at the intersection of cutting-edge biotechnology and immunology, making it a noteworthy participant in the burgeoning biopharmaceutical sector. Its work is significant in the market as it addresses unmet medical needs, offering hope for transformative advancements in patient care in the face of complex and debilitating diseases.